Table 6.
Estimations of Morquio A point prevalence from birth prevalence data
| Birth prevalence (per 10, 000)* | Estimated MPS IVA point prevalence # | Estimated MPS IVA point prevalence per 10,000 | Estimated people alive with MPSIVA | |
|---|---|---|---|---|
| Australia KOL [27] | 0.04 | 1 per 810,000 | 0.0123 | 27 |
| Germany [32] | 0.038 | 1 per 835,000 | 0.0120 | 97 |
| UAE (Emirates) [25] | 0.14 | 1 per 217,000 | 0.0460 | 25 |
| Australia [31] | 0.0497 | 1 per 652,000 | 0.0153 | 34 |
| Canada (BC) [30] | 0.048 | 1 per 668,000 | 0.0150 | 7 |
| Japan (POR) [35] | 0.02 | 1 per 1,664,000 | 0.0060 | 76 |
Abbreviations: BC British Columbia, KOL Key Opinion Leader, POR Patient organisation representative, NI Northern Ireland, UAE United Arab Emirates, UK United Kingdom, W West. *Calculated by authors from Tables 4 and 5; #average point prevalence for study period.
Estimated MPS IVA patients alive = MPSIVA point prevalence × population.